Earnings call transcript: ModivCare Q4 2024 misses EPS, stock rises 5.65%
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings report revealed several challenges: operational issues due to Medicaid redetermination, flat revenue growth, and a 20% decline in adjusted EBITDA. Despite some cost savings, the guidance was lowered, and management's unclear responses in the Q&A raised concerns. The financial health is strained with fully drawn revolver balance and reliance on new debt instruments. These factors, combined with the economic pressures and membership reductions, suggest a negative sentiment likely leading to a stock price decline of -2% to -8%.
Key Financial Performance
Q4 Revenue $702,800,000, flat year-over-year; gains in PCS offset by declines in monitoring and NEMT segments.
Full Year Revenue $2,790,000,000, a slight increase of just over 1% year-over-year; driven by a 4.1% increase in PCS revenue.
Q4 Adjusted EBITDA $40,400,000, or 5.7% of revenue; a decrease of approximately 20% year-over-year, primarily due to $28,000,000 impact from Medicaid redetermination.
Full Year Adjusted EBITDA $161,100,000, reflecting a decrease of approximately 20% year-over-year; impacted by $28,000,000 from Medicaid redetermination and $16,000,000 from NEMT business development activities.
NEMT Revenue $495,000,000, relatively flat year-over-year; average monthly members decreased by approximately 11% year-over-year.
NEMT Adjusted EBITDA $27,600,000, with a margin of 5.6%; sequential decline primarily driven by utilization effects.
PCS Revenue $186,600,000, increased by 3% year-over-year; driven by 3.5% growth in revenue per hour.
PCS Adjusted EBITDA $17,500,000, or 9.4% of revenue; included state-based quality incentive payments.
RPM Revenue $19,200,000, decreased by about 1% sequentially; primarily due to churn in MA membership.
RPM Adjusted EBITDA $6,800,000, with a 35% margin.
Free Cash Flow (Q4) $24,700,000, consisting of net cash provided by operating activities of $30,000,000 and capital expenditures of $5,300,000.
Net Contract Receivables $95,200,000, compared to $63,100,000 last quarter; significant increase year-over-year.
Net Working Capital Decreased by $68,700,000 in 2024, driven by repayment of contract settlements.
Revolver Balance $269,000,000, fully drawn at year-end.
Cash Position $113,000,000 at year-end.
Cost per Trip (NEMT) Decreased from $42 in Q4 2023 to $40 in Q4 2024; contributing to $35,000,000 in savings in 2024.
Payroll and Other Expense per Trip (NEMT) $5.67, at record low levels, 18% lower than the prior year.
Service Expense per Trip (NEMT) Decreased by approximately 1% sequentially.
Purchased Service Expense per Trip (NEMT) Decreased by 1% quarter over quarter and 4.3% year over year to $40.42.
Operating Highlights
New Product Launches: Launched new chronic conditions monitoring and virtual care management services, expanding beyond traditional monitoring.
Market Expansion: Identified active pipeline surpassing $300,000,000 in annual contract value within managed Medicaid and Medicare Advantage.
Contract Renewals: Expect multiple state contracts to come up for renewal in 2025, with strong positioning for retention.
Operational Efficiencies: Achieved $35,000,000 in cost savings through automation and AI-powered trip assignment technology.
Cash Flow Improvements: Transitioning to fee-for-service contracts to improve cash flow conversion timing.
Strategic Appointments: Appointed Chad Sandler as Chief Transformation Officer to drive execution and long-term success.
Divestiture Strategy: Initiated a process to monetize select segments, particularly the monitoring platform, due to strong market demand.
Risk or Challenges
Market Disruption: The company faced unprecedented disruption in 2024 due to Medicaid redetermination, increased healthcare utilization, and Medicare Advantage reimbursement cuts, leading to significant financial strain and unpredictable revenue shifts.
Client Financial Strain: Financial pressures on clients resulted in the attrition of select contracts, leading to a net business loss of approximately $200,000,000 in annual revenue for 2025.
Cash Flow and Working Capital Risks: The company experienced challenges with cash flow and working capital timing, necessitating proactive measures to address these risks.
Regulatory Risks: Potential cuts to Medicaid budgets and eligibility changes pose risks to the NEMT business, although the company expects to manage these through contract negotiations.
Contract Structure Risks: The transition from shared risk contracts to fee-for-service structures may create uncertainties in revenue and cash flow, particularly in the NEMT segment.
Operational Challenges: The company faced operational challenges due to the need for renegotiating contracts and managing the impacts of Medicaid redetermination on membership and revenue.
Economic Factors: The overall economic environment, including inflationary pressures, has impacted operational costs and client financial stability.
Guidance & Outlook
Capital Raise: Secured an incremental $75,000,000 term loan and $30,000,000 in new second lien notes to strengthen capital position.
Divestiture Process: Engaged in a strategic alternatives committee to explore monetization of select segments, particularly the monitoring platform.
Technology Investment: Continued strengthening technology-enabled platforms across NEMT, personal care, and monitoring.
Board Appointments: Appointed Chad Sandler as Chief Transformation Officer and added Alec Cunningham and David Mounts Gonzales to the Board to enhance strategic execution.
Contract Structure Transition: Transitioning approximately 25% of revenue to fee-for-service contracts to improve cash flow and reduce working capital challenges.
2025 Revenue Expectations: No formal guidance provided for fiscal 2025 due to ongoing strategic review and anticipated portfolio changes.
NEMT Revenue Outlook: Expect contract losses in 2025 to be partially offset by new wins, with a focus on pricing improvements and operational efficiencies.
Personal Care Services Growth: Expect modest organic hours growth in PCS, driven by rate increases and improved management.
Remote Patient Monitoring Growth: Anticipate modest volume growth in RPM driven by Medicaid LTSS referral volumes and clinical program growth.
Cash Flow Expectations: Expect to return to positive free cash flow in the back half of 2025, with a focus on improving working capital dynamics.
Shareholder Return Plan
Incremental Term Loan: Secured an incremental $75,000,000 term loan.
New Second Lien Notes: Secured $30,000,000 in new second lien notes, subject to shareholder approval.
Shareholder Approval Date: Shareholder approval for the new second lien notes is scheduled for March 13, 2025.
Key Q&A
Earnings Word Cloud
MODV Transcript
The earnings call reveals several concerns: lowered 2024 EBITDA guidance, increased operational costs, and regulatory challenges impacting EBITDA. Despite some positive aspects like EPS beat and revenue growth, the uncertainty in cash flow and contract risks overshadow these. The Q&A highlights management's vague responses, particularly regarding Medicaid cuts and contract renewals. These factors, combined with the flat revenue and adjusted EBITDA, suggest a negative sentiment. The lack of a market cap limits precise impact prediction, but the overall sentiment points to a negative stock price movement in the range of -2% to -8%.
The earnings report revealed several challenges: operational issues due to Medicaid redetermination, flat revenue growth, and a 20% decline in adjusted EBITDA. Despite some cost savings, the guidance was lowered, and management's unclear responses in the Q&A raised concerns. The financial health is strained with fully drawn revolver balance and reliance on new debt instruments. These factors, combined with the economic pressures and membership reductions, suggest a negative sentiment likely leading to a stock price decline of -2% to -8%.
The earnings call reveals flat revenue growth, a significant decrease in EBITDA, and challenges in key segments like NEMT. Despite some positive aspects, such as improved cash flow management, the financial health appears strained with a fully drawn revolver and additional debt. The Q&A session highlighted uncertainties and vague responses from management, particularly regarding asset sales and membership numbers. These factors, combined with regulatory and economic pressures, suggest a negative outlook for the stock price in the short term.
The earnings call reveals mixed financial performance: slight revenue growth and modest improvements in personal care, but declining margins in NEMT and RPM. The Q&A section highlights management's optimism about transitioning to fee-for-service and deleveraging but lacks clarity on certain financial impacts. The reaffirmed revenue guidance and expected cost savings are positive, but the lowered EBITDA guidance and high debt levels are concerning. Overall, the sentiment is neutral, reflecting balanced positives and negatives, with no strong catalysts for significant stock price movement in the short term.
MODV Slides
MODV Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
